vs

Side-by-side financial comparison of CaliberCos Inc. (CWD) and NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC). Click either name above to swap in a different company.

CaliberCos Inc. is the larger business by last-quarter revenue ($4.1M vs $2.9M, roughly 1.4× NEUROONE MEDICAL TECHNOLOGIES Corp). NEUROONE MEDICAL TECHNOLOGIES Corp runs the higher net margin — -49.7% vs -188.3%, a 138.6% gap on every dollar of revenue. On growth, NEUROONE MEDICAL TECHNOLOGIES Corp posted the faster year-over-year revenue change (-11.7% vs -52.5%). Over the past eight quarters, NEUROONE MEDICAL TECHNOLOGIES Corp's revenue compounded faster (44.9% CAGR vs -57.6%).

CaliberCos Inc. is a U.S.-headquartered alternative asset management firm focused primarily on real estate investments. It offers a diverse suite of investment vehicles covering commercial, residential, and industrial real estate assets, serving institutional investors, high-net-worth individuals, and retail clients across North America. It also delivers asset management, property operation, and value-add real estate development services to support consistent long-term returns for investors.

NeuroOne Medical Technologies Corp is a medical technology company specializing in the development and commercialization of diagnostic and therapeutic neurological devices for conditions including epilepsy, movement disorders, and chronic pain. Its core products include minimally invasive cortical monitoring electrodes and neurostimulation systems, primarily serving neurology and neurosurgical care providers across North America.

CWD vs NMTC — Head-to-Head

Bigger by revenue
CWD
CWD
1.4× larger
CWD
$4.1M
$2.9M
NMTC
Growing faster (revenue YoY)
NMTC
NMTC
+40.8% gap
NMTC
-11.7%
-52.5%
CWD
Higher net margin
NMTC
NMTC
138.6% more per $
NMTC
-49.7%
-188.3%
CWD
Faster 2-yr revenue CAGR
NMTC
NMTC
Annualised
NMTC
44.9%
-57.6%
CWD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CWD
CWD
NMTC
NMTC
Revenue
$4.1M
$2.9M
Net Profit
$-7.7M
$-1.4M
Gross Margin
54.2%
Operating Margin
-196.6%
-59.0%
Net Margin
-188.3%
-49.7%
Revenue YoY
-52.5%
-11.7%
Net Profit YoY
32.2%
-180.5%
EPS (diluted)
$1.95
$-0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CWD
CWD
NMTC
NMTC
Q4 25
$4.1M
$2.9M
Q3 25
$3.6M
$2.7M
Q2 25
$5.1M
$1.7M
Q1 25
$7.3M
$1.4M
Q4 24
$8.7M
$3.3M
Q3 24
$11.3M
$272.3K
Q2 24
$8.2M
$825.8K
Q1 24
$23.0M
$1.4M
Net Profit
CWD
CWD
NMTC
NMTC
Q4 25
$-7.7M
$-1.4M
Q3 25
$-4.4M
$-1.6M
Q2 25
$-5.3M
$-1.5M
Q1 25
$-4.4M
$-2.3M
Q4 24
$-11.4M
$1.8M
Q3 24
$146.0K
Q2 24
$-4.7M
$-2.8M
Q1 24
$-3.8M
$-2.9M
Gross Margin
CWD
CWD
NMTC
NMTC
Q4 25
54.2%
Q3 25
55.8%
Q2 25
53.9%
Q1 25
55.6%
Q4 24
58.9%
Q3 24
51.8%
Q2 24
34.1%
Q1 24
28.3%
Operating Margin
CWD
CWD
NMTC
NMTC
Q4 25
-196.6%
-59.0%
Q3 25
-129.6%
-50.0%
Q2 25
-112.4%
-111.2%
Q1 25
-62.7%
-193.3%
Q4 24
-236.8%
52.3%
Q3 24
0.0%
Q2 24
-65.0%
-338.3%
Q1 24
-22.9%
-209.5%
Net Margin
CWD
CWD
NMTC
NMTC
Q4 25
-188.3%
-49.7%
Q3 25
-120.2%
-59.1%
Q2 25
-104.5%
-88.5%
Q1 25
-60.7%
-163.8%
Q4 24
-247.6%
54.5%
Q3 24
1.3%
Q2 24
-57.8%
-335.1%
Q1 24
-16.6%
-207.3%
EPS (diluted)
CWD
CWD
NMTC
NMTC
Q4 25
$1.95
$-0.03
Q3 25
$-1.65
$-0.05
Q2 25
$-4.15
$-0.03
Q1 25
$-3.85
$-0.07
Q4 24
$-10.15
$0.06
Q3 24
$0.12
Q2 24
$-4.34
$-0.10
Q1 24
$-3.53
$-0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CWD
CWD
NMTC
NMTC
Cash + ST InvestmentsLiquidity on hand
$2.9M
$3.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.3M
$6.4M
Total Assets
$135.4M
$8.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CWD
CWD
NMTC
NMTC
Q4 25
$2.9M
$3.6M
Q3 25
$10.9M
$6.6M
Q2 25
$683.0K
$8.0M
Q1 25
$1.6M
$1.3M
Q4 24
$2.3M
$1.1M
Q3 24
$1.6M
$1.5M
Q2 24
$1.8M
$1.6M
Q1 24
$2.1M
$2.4M
Stockholders' Equity
CWD
CWD
NMTC
NMTC
Q4 25
$1.3M
$6.4M
Q3 25
$4.2M
$7.1M
Q2 25
$-19.9M
$8.2M
Q1 25
$-15.8M
$1.1M
Q4 24
$-12.6M
$2.9M
Q3 24
$-3.8M
$822.0K
Q2 24
$-4.7M
$3.0M
Q1 24
$-745.0K
$3.9M
Total Assets
CWD
CWD
NMTC
NMTC
Q4 25
$135.4M
$8.6M
Q3 25
$82.6M
$10.8M
Q2 25
$59.3M
$10.8M
Q1 25
$103.6M
$4.5M
Q4 24
$105.5M
$6.5M
Q3 24
$158.6M
$5.4M
Q2 24
$195.2M
$4.9M
Q1 24
$201.5M
$5.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CWD
CWD
NMTC
NMTC
Operating Cash FlowLast quarter
$-12.1M
$-3.1M
Free Cash FlowOCF − Capex
$-3.2M
FCF MarginFCF / Revenue
-109.1%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CWD
CWD
NMTC
NMTC
Q4 25
$-12.1M
$-3.1M
Q3 25
$-4.6M
$-1.5M
Q2 25
$-1.2M
$-1.5M
Q1 25
$-1.7M
$-56.1K
Q4 24
$555.0K
$208.0K
Q3 24
$-74.0K
$-11.0M
Q2 24
$1.4M
$-2.4M
Q1 24
$-1.5M
$-2.2M
Free Cash Flow
CWD
CWD
NMTC
NMTC
Q4 25
$-3.2M
Q3 25
Q2 25
$-1.5M
Q1 25
Q4 24
$183.6K
Q3 24
$-11.1M
Q2 24
$-2.4M
Q1 24
$-2.2M
FCF Margin
CWD
CWD
NMTC
NMTC
Q4 25
-109.1%
Q3 25
Q2 25
-89.0%
Q1 25
Q4 24
5.6%
Q3 24
-4088.4%
Q2 24
-287.6%
Q1 24
-160.2%
Capex Intensity
CWD
CWD
NMTC
NMTC
Q4 25
1.4%
Q3 25
Q2 25
2.8%
Q1 25
Q4 24
0.7%
Q3 24
44.1%
Q2 24
1.8%
Q1 24
2.3%
Cash Conversion
CWD
CWD
NMTC
NMTC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.12×
Q3 24
-0.51×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons